Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma, Published online: 27 February 2019; doi:10.1038/s41586-019-0987-8
A subtype of early-stage hepatocellular carcinoma characterized by disrupted cholesterol homeostasis and associated with a poor prognosis responds to treatment with the SOAT1 inhibitor avasimibe in a patient-derived xenograft mouse model.
Comments
Post a Comment